ESRD occurrence | Crude Hazard ratio, 95% CI, and P-value | Adjusted for confounders, gender, and systolic BP Hazard ratio, 95% CI, and P-value |
---|---|---|

Phosphate (1 mg/dl) | 3.30 (2.46–4.43), P < 0.001 | 1.84 (1.27–2.67), P = 0.001 |

Treatment with Ramipril (0 = no; 1 = yes) | 0.48 (0.29–0.79), P = 0.004 | |

Albumin (1 g/dl) | 0.43 (0.26–0.73), P = 0.002 | |

Hemoglobin (1 g/dl) | 0.90 (0.78–1.02), P = 0.11 | |

Iohexol GFR (1 ml/min/1.73m^{2}) | 0.94 (0.92–0.96), P < 0.001 | |

Urinary Protein (1 g/24 h) | 1.11 (1.02–1.21), P = 0.01 | |

Gender (0 = M; 1 = F) | 1.71 (0.94–3.10), P = 0.08 | |

Systolic pressure (1 mmHg) | 1.03 (1.01–1.04), P = 0.001 |

Combined end point (ESRD/creatinine doubling) | Crude Hazard ratio, 95% CI, and P-value | Adjusted for confounders, gender, and systolic BP Hazard ratio, 95% CI, and P-value |
---|---|---|

Phosphate (1 mg/dl) | 2.87 (2.18–3.77), P < 0.001 | 1.66 (1.18–2.33), P = 0.004 |

Treatment with Ramipril (0 = no; 1 = yes) | 0.49 (0.31–0.79), P = 0.003 | |

Albumin (1 g/dl) | 0.50 (0.31–0.82), P = 0.006 | |

Hemoglobin (1 g/dl) | 0.92 (0.81–1.05), P = 0.20 | |

Iohexol GFR (1 ml/min/1.73m^{2}) | 0.95 (0.93–0.97), P < 0.001 | |

Urinary protein (1 g/24 h) | 1.11 (1.02–1.20), P = 0.01 | |

Gender (0 = M; 1 = F) | 1.51 (0.87–2.63), P = 0.14 | |

Systolic pressure (1 mmHg) | 1.02 (1.01–1.03), P = 0.002 |

The approach to multivariate Cox's regression analysis is described in detail in the Methods section. Data are expressed as hazard ratio, 95% CI, and

*P*-values.